A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment
MetadataShow full item record
The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evaluate hospital discharge planning in relation to three different sets of regulations. We studied 100 patients, 78 females and 22 males, aged 13 to 79 years (mean 44.40آ±15.83 years) with DTC, in three Groups who were treated with 3.7, 5.5 or 7.4GBq of 131I, respectively. The external whole-body dose rates following oral administration of 131I were measured after each one of the first three hospitalization days. A multivariant linear analysis was performed, considering exposure rates as dependent variables to the administered dose for treatment, age, gender, regional and/or distant metastases, thyroglobulin (Tg), antibodies to Tg and thyroid remnant in the three dose groups. We found that the exposure rates after each of the three first days of hospitalization were 30, 50 and 70?Svh-1 at 1m. All our DTC patients had an acceptable dose rate on days 2 and 3 that allowed their hospital discharge. After only 1 day of hospitalization, just 3/11 cases showed not permissible exposure rates above 70?Svh-1. In conclusion, it is the opinion of the authors that after measuring the exposure rates, most treated, DTC patients could be discharged after only one day of hospitalization, even some of those treated with high doses of 131I (7.4GBq). Patients, who received the higher doses of 131I, should not be released before their individual exposure rate is measured.
Showing items related by title, author, creator and subject.
Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma Asli, IN; Baharfard, N; Shafiei, B; Tabei, F; Javadi, H; Seyedabadi, M; Nabipour, I; Assadi, M (2009)Three days following administration of radioactive iodine in 38 patients, exposure rates such as dose rate close to the dress (D0), dose rate of dress at 1 m (D1), dose rate close to the bedsheet (B0), dose rate of bedsheet ...
Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with 131I: Comparison of the efficacy of pantoprazole, metoclopra-mide, and ondansetron – a randomized clinical trial [Behandlung gastrointestinaler beschwerden unter 131I-therapie bei patienten mit differenzier-tem schilddrüsenkarzinom: Vergleich der wirksamkeit von pantoprazol, meto-clopramid und ondansetron – eine randomisierte klinische prüfung] Mirzababaee, M; Shafiei, B; Seifollahi, S; Motazdian, M; Fatholahi, L; Delavari, S; Naghshine, R; Baharfar, N; Tabeie, F; Javadi, H; Assadi, M; Asli, IN (2014)Objective: To compare safety and efficacy of pantoprazol, metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients. ...
Tabei, F; Asli, IN; Azizmohammadi, Z; Javadi, H; Assadi, M (2012)Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the management of differentiated thyroid cancer (DTC). Concerns regarding stochastic radiogenic risks have led to regulatory criteria ...